TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must be 18-70 years male or female~* Identified or clinically diagnosed IFI participants or high risk population who are resistant to, or recurrent from, or intolerable to, or may suffer toxic reaction from standard antifungal treatment.~* Sign informed consent form~Exclusion Criteria:~* Female participants who are pregnant or are nursing.~* Participants with known or suspected hypersensitivity or idiosyncratic reaction to azole agents or amphotericin B~* Participants with progressive nervous system diseases( excluding those IFI caused)~* Participants who take the following drugs known with interference with azole antifungal preparations~  * terfenadine, cisapride, and ebastine within 24 hours before entry~ * astemizole at entry or within 10 days before entry~ * cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, isoniazid atharanthine and anthracyclines within 24 hours before entry~* The drugs listed above are prohibited during the investigation~* Serious organ diseases except hematological disorder such as cardiac or neurologic disorders or impairment expected to be unstable or progressive during the course of this study (eg, seizures or demyelinating syndromes, acute myocardial infarction within 3 months of study entry, myocardial ischemia, congestive heart failure, atrial fibrillation with ventricular rate \<60/min, or history of torsades de pointes, symptomatic ventricular or sustained arrhythmias), unstable electrolyte abnormalities.~* Participants having an ECG with a prolonged QTc interval: QTc greater than 450 msec for men and greater than 470 msec for women.~* Expected to take during investigation or is taking systemic antifungal treatment~* Participants with severe renal insufficiency (estimated creatinine clearance less than 50 mL/minute or likely to require dialysis during the study), ALT,AST AKP or total bilirubin are \>2×ULN.~* Participants expected to survive no more than 72hrs~* Participants receiving artificial aeration and will not withdraw within 24hrs~* Participants who have used any investigational drugs or biologic agents or anticipated other clinical trials within 30 days of study entry.~* Prior enrollment in this study.~* History of alcohol and/or drug abuse.~* Participants cannot be compliant in investigator's opinion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Posaconazole (Type: EXPERIMENTAL): Posaconazole 400 mg twice a day (BID) oral suspension for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Prior participation in and the successful completion of the R727-CL-1003 study (NCT01266876).~2. Patients must be on a stable daily statin regimen for at least 3 weeks before prior to entry into the study~3. A negative urine pregnancy at the screening/baseline visit for women of childbearing potential~Key Exclusion Criteria:~1. Reported a drug-related serious adverse event (SAE) or drug-related clinical or laboratory adverse event (AE) in the R727-CL-1003 study that resulted in early termination or withdrawal~2. Significant protocol deviation in R727-CL-1003, such as non-compliance by the investigator or patient~3. Low-density lipoprotein (LDL) apheresis within 12 months before the screening/baseline visit~Note: Other exclusion criteria applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Matched to Alirocumab (Type: PLACEBO_COMPARATOR): Participants who received placebo in parent study (NCT01576484), has received a subcutaneous injection of placebo matched to alirocumab every 2 weeks for 4 years in this study.
- Alirocumab 150 mg (Type: EXPERIMENTAL): Participants who received alirocumab in parent study (NCT01576484), has received a subcutaneous injection of alirocumab 150 milligram (mg) every 2 weeks for 4 years in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Low-dose Ticagrelor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with coronary artery disease~Exclusion Criteria:~* younger than 18 years of age;~* anti-platelet therapy with clopidogrel or ticagrelor for less than 5 days;~* previous or current treatment with any other potentially confounding drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ticagrelor 45mg bidpo. (Type: EXPERIMENTAL): To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
- ticagrelor 90mg qdpo. (Type: EXPERIMENTAL): To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
- ticagrelor 90mg bidpo. (Type: ACTIVE_COMPARATOR): To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
- clopidogrel 75mg qdpo. (Type: ACTIVE_COMPARATOR): To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are a patient admitted to a Scripps Mercy Hospital,~* Consider yourself Hispanic/Latino, of any race~* Are 18 years of age or older,~* Speak English or Spanish,~* Have type 2 diabetes and A1c ≥ 7% in the last 90 days, and~* Have a cellphone that can receive/send text messages.~Exclusion Criteria:~* Are pregnant,~* Are currently participating in another diabetes or COVID-19 related study, or~* Do not meet all eligibility inclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DD-CA (Type: EXPERIMENTAL): In the DD-CA arm, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with added COVID support messages.
- Usual Care (UC) (Type: ACTIVE_COMPARATOR): UC participants will not receive the added COVID support messages, both arms will have a referral placed to the Diabetes Transitions Service (DTS) as part of usual care at the time of discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients that have signed informed consent and are \>/= 40 years of age.~* Patients with stable COPD according to GOLD 2011.~* Patients with a post-bronchodilator FEV1 of \>/= 30% and \< 80% predicted and a post-bronchodilator FEV1/FVC \<0.70.~* Current or ex-smokers who have a smoking history of at least 10 pack years.~* Patients with an mMRC grade 2 or greater.~Exclusion Criteria:~* Patients with Type I or uncontrolled Type II diabetes - Patients with a history of long QT syndrome or whose QTc measured at Visit 101 (Fridericia method) is prolonged (\>450 ms for males and females) and confirmed by a central assessor. (These patients should not be re-screened.)~* Patients who have a clinically significant ECG abnormality at Visit 101 or Visit 102. (These patients should not be re-screened.)~* Patients with a history of malignancy of any organ system, treated or untreated, within the last five years.~* Patients with narrow-angle glaucoma, BPH or bladder-neck obstruction or moderate-severe renal impairment or urinary retention.~* Patients who had a COPD exacerbation within 6 weeks prior to screening.~* Patients who have a respiratory tract infection within 4 weeks prior to screening.~* Patients requiring long term oxygen therapy prescribed for more than 12 hr per day.~* Patients with a history of asthma. 8. Patients with an onset of respiratory symptoms, including COPD diagnosis, prior to age 40 years.~* Patients with a blood eosinophil count of greater than 600 mm/3 during run-in.~* Patients with concomitant pulmonary disease.~* Patients with a diagnosis of alpha-1 anti-trypsin deficiency.~* Patients with active pulmonary tuberculosis.~* Patients in the active phase of a pulmonary rehabilitation programme.~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVA149 (Type: EXPERIMENTAL): 27.5/12.5 ug twice daily (b.i.d.) Single Dose Dry Powder Inhaler (SDDPI
- QAB149 (Type: ACTIVE_COMPARATOR): 27.5 ug b.i.d.
- NVA237 (Type: ACTIVE_COMPARATOR): 12.5 ug b.i.d.
- Placebo (Type: PLACEBO_COMPARATOR): b.i.d.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants planned to receive a tooth extraction of one mandibular impacted wisdom tooth~* Participants who require bone removal and separation of the crown at tooth extraction~* Participants whose intensity of pain associated with tooth extraction within 2 hours after tooth extraction is greater than or equal to 50.0 millimeter on the visual analog scale (VAS)~* Participants who did not undergo general anesthesia or sedation at tooth extraction~* Participants without an abnormality (including laboratory test values) corresponding to Grade 3 in the Criteria for severity classification of adverse drug reactions during the pretreatment observation period~Exclusion Criteria:~* Participants with conditions for which tramadol is contraindicated~* Participants with conditions for which acetaminophen is contraindicated~* Participants with history of convulsions or the possibility of convulsive seizures~* Pregnant participants or those who may be pregnant, lactating mothers, and those who wish pregnancy during the study period~* Participants with concurrent, previous, or possible alcohol dependence, drug dependence or narcotic addiction

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Tramadol plus Acetaminophen and Placebo (Type: EXPERIMENTAL): Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively, along with two oral capsules of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed greater than or equal to (\>=) 50.0 millimeter (mm) on the Visual Analog Scale (VAS), score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
- Tramadol and Placebo (Type: EXPERIMENTAL): Tramadol hydrochloride will be administered as single oral dosing of two capsules once at a dose of 75 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed \>= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
- Acetaminophen and Placebo (Type: EXPERIMENTAL): Acetaminophen will be administered as single oral dosing of two capsules once at a dose of 650 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed \>= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diabetes type 2~* HbA1c 8% or higher~* age 25 to 65~Exclusion Criteria:~* alteration in insulin sensitivity such as major surgery, infection, renal failure (Glomerular Filtration Rate \< 50),~* glucocorticoid treatment,~* recent (within 2 weeks) serious hypoglycemic episode (requires assistance of another),~* simultaneous participating in another clinical study,~* using any type of insulin,~* sight or hearing impaired,~* active proliferative retinopathy or maculopathy require treatment within 6 months prior to screening,~* breast feeding,~* pregnancy or nursing of the intention of becoming pregnant or~* not using adequate contraceptive measures.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- BIAsp 30 (Type: EXPERIMENTAL): patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
- NPH/Reg (Type: ACTIVE_COMPARATOR): patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with primary RLS, based on the International RLS Study Group Diagnostic Criteria.~Exclusion Criteria:~* A sleep disorder (e.g., sleep apnea) that may significantly affect the assessment of RLS;~* Neurologic disease or movement disorder (e.g., diabetic neuropathy, Parkinson's disease, Multiple Sclerosis, dyskinesias, and dystonias);~* Abnormal laboratory results, electrocardiogram (ECG) or physical findings;~* Pregnant or lactating women;~* Women of childbearing potential who are not practicing an acceptable method of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GEn (XP13512) 1200 mg (Type: EXPERIMENTAL): GEn (XP13512) 1200 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study in Elective Total Hip Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled to undergo elective total hip replacement surgery or a revision of at least one component of a total hip replacement performed \> 6 months prior to study entry~Exclusion Criteria:~* Pregnant or nursing women, or women of childbearing potential who are not using an effective contraceptive method and who do not have a negative pregnancy test performed immediately before randomization~* Known progressive malignant disease~* Ischemic stroke in the last 3 months~* Myocardial infarction (MI) in the last 3 months~* Any major orthopedic surgery in the 3 months prior to study start~* Clinical signs or symptoms of DVT or PE within the last 12 months or symptoms of post phlebitic syndrome (these conditions may confound DVT/PE assessments)~* Treatment with other antithrombotic agents within 7 days prior to surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atazanavir/r + Lamivudine Dual Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* HIV positive patients 18 years of age or older who signed an informed consent form~* Already on cART, without any treatment interruption.~* Treated with a cART regimen containing atazanavir boosted with ritonavir since at least 3 months~* With full virological suppression (VL\<50 copies/mL) for a minimum of six months and in at least in two consecutive determination 3 months +/-2 weeks apart from each other~* With CD4 cell count \>200 since at least 6 months and without opportunistic infections or other AIDS-related events since at least one year before screening~Exclusion Criteria:~* Previous virological failure on a lamivudine- or PI-containing regimen or previous exposure to lamivudine-containing suboptimal antiretroviral regimens~* Patients with at least a single viral load blip over 200 copies/mL~* Patients with M184V or major atazanavir resistance mutation at previous genotypic resistance test (historical genotype)~* Pregnancy or lactation, planned pregnancy in the short-term~* Patients with HBsAg positive chronic HBV infection~* Patients who experienced major toxicities related to any of the study drugs in the past~* Patients with grade 4 laboratory abnormalities at baseline (excluding lipid profile and plasma bilirubin concentration).~* Patients with non-AIDS related illnesses which could, in the Clinician's judgement, jeopardize the patient's compliance to the study procedures (i.e. Child-Pugh B or higher liver cirrhosis, active cancers on treatment...).~* Patients treated with proton-pump inhibitors or other concomitant medication with potential for interactions reducing exposure to atazanavir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Switch (Type: EXPERIMENTAL): Switch to Atazanavir 300 mg with ritonavir 100 mg plus lamivudine 300 mg
- continue (Type: NO_INTERVENTION): Continue Atazanavir 300 mg with ritonavir 100 mg with the same NRTI backbone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Advanced medical illness with a life expectancy of 1 to 6 months~2. No clinically significant laxation within 48 hours prior to the first dose of study drug~3. On stable opioid and laxative regimen for a least 3 days prior to treatment~4. Age greater than 18years~5. Females of child-bearing age must have a negative pregnancy test.~Exclusion Criteria:~1. Females who are pregnant or nursing.~2. Previous treatment with MNTX or prior treatment with naltrexone or naloxone for treatment of OIC~3. Any disease process suggestive of gastrointestinal obstruction~4. Fecal ostomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 3 (Type: PLACEBO_COMPARATOR): None
- Arm 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Participation for an individual patient is expected to be approximately 72 weeks.~Patients who complete 72 weeks of treatment may be eligible to receive treatment for up to 52 weeks during the follow-up treatment period and patients who completed the 124 weeks of treatment may be eligible to enter the additional long-term follow-up period.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- LUM001 (Maralixibat) (Type: EXPERIMENTAL): LUM001 also known as Maralixibat (MRX) administered orally up to twice each day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete